PEPTIDE CORTEXThe library
← The library

Cagrilintide

researchMetabolic/Weight
Evidence grade
DResearch/compounded/adjunct (no established FDA indication)
Cardiovascular · 0–5 · separate axis
1
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeMetabolic / Weight loss
MechanismLong-acting amylin analog; increases satiety
EffectsMore satiety + slower digestion; improves post-meal blood sugar
DosingTrial doses (not approved): phase 2 arms of 0.3, 0.6, 1.2, 2.4 or 4.5 mg once weekly for 26 weeks; 2.4 mg once weekly as the cagrilintide-alone arm of phase 3 REDEFINE 1.
Bottom linePopular in research/compounding; human safety/benefit not well-established.
Protocols · as published3 sourced
Clinical trialPhase 2 dose-finding (Lau, Lancet 2021)
RouteSubcutaneous injection
FrequencyOnce weekly, 26 weeks
StartingNot given in the abstract
EscalationDose-escalation period of up to 6 weeks; step sizes not published in the abstract
TargetArms: 0.3, 0.6, 1.2, 2.4 or 4.5 mg once weekly. Weight loss 6.0% to 10.8% vs 3.0% placebo.
Maximum4.5 mg weekly (maximum studied)
Clinical trialREDEFINE 1 cagrilintide-alone arm (NEJM 2025)
RouteSubcutaneous injection
FrequencyOnce weekly, 68 weeks
StartingNot described separately for the monotherapy arm
EscalationNot described separately for the monotherapy arm
Target2.4 mg once weekly: -11.8% weight change (trial-product estimand)
Community protocol — not clinically establishedCommunity guide
RouteSubcutaneous injection
FrequencyOnce weekly
Starting0.25 mg/week, weeks 1-4
Escalation0.5 mg weeks 5-8, 1.0 mg weeks 9-12, 1.7 mg weeks 13-16, 2.4 mg from week 17. Copies the CagriSema/semaglutide ladder; no monotherapy trial published it.
Target2.4 mg weekly
CycleShort 16 weeks, standard 26-32 weeks, long 68 weeks
Batches on file1
5 mgJA-63073 · 2025-0499.09%
Read with10
Cautions & interactions

Not FDA-approved; unknown long-term safety; avoid self-administration

No well-established interaction profile for non-approved peptides; avoid combining multiple research compounds; discuss meds with clinician.

CV 1 of 5 — Limited direct cardiovascular evidence.